Updated on 24 September 2013
The report pointed out that the sales of products affected by this regulation fell nine percent in August from a year earlier. The IMS report explained that this was mainly on account of the delay in the delivery of new stocks with changed retail prices from manufacturers, coupled with opposition to the proposed reduction in prices of these drugs.
The report further specified other contributing factors like the monsoon rain in August, which was milder as compared to the same period in the previous year. The report explained that this resulted in a 4.7 percent decline in sales of drugs for certain therapies, especially anti-infectives that contribute to about 16 percent of the drug market.